Changes in glitazone use among office-based physicians in the U.S., 2003-2009.
about
State Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warningGeographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans AffairsAmbulatory treatment of type 2 diabetes in the U.S., 1997-2012.Rosiglitazone use and associated adverse event rates in Canada between 2004 and 2010.Retrospective review of superficial femoral artery stenting in diabetic patients: thiazolidinedione use may decrease reinterventions.Assessing the association of pioglitazone use and bladder cancer through drug adverse event reportingUtilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings.Trends in Antihyperglycemic Medication Prescriptions and Hypoglycemia in Older Adults: 2002-2013Drug safety: withdrawn medications are only part of the pictureImpact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.Medication usage, treatment intensification, and medical cost in patients with type 2 diabetes: a retrospective database studyInfluence of health warnings on the use of rosiglitazone and pioglitazone in an area of Spain: A time-series studyThiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs.How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?Novel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness.Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications.New Initiation of Long-Acting Opioids in Long-Stay Nursing Home Residents.Impact of rosiglitazone safety alerts on oral antidiabetic sales trends: a countrywide study in Portugal.The Impact of FDA Regulatory Activities on Incident Dispensing of LABA-Containing Medication: 2005-2011.Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan.Solubility of pioglitazone hydrochloride in binary and ternary mixtures of water, propylene glycol, and polyethylene glycols 200, 400, and 600 at 298.2 kDrug vs class-specific black box warnings: does one bad drug spoil the bunch?Fucosylated chondroitin sulfate from Acaudina molpadioides improves hyperglycemia via activation of PKB/GLUT4 signaling in skeletal muscle of insulin resistant mice.Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations.
P2860
Q24604853-18660188-13B6-4C5F-A459-AD8EBF373C2CQ30359158-F48770A6-0706-46D7-8B88-D9AE9B7B97D3Q34259412-C994DB93-A52E-4803-89F8-ACFEDEBDFDC4Q34623567-B65A4C17-6172-432E-8A4D-FF4FABCC83B0Q34728813-1B8F1CD3-A39B-4A5D-AD4E-DF28E82335BAQ35043204-8D27DAED-B73D-4946-8337-EDFDE0AD5498Q35141084-7D76488D-61B3-41CE-9E37-A30E9D35C6FFQ35763657-69C97A56-C8F5-4B59-AACF-A7CB2902E72AQ35922956-71EDF440-E17A-4CE9-BED1-7CE79A704D78Q35928690-948AF0EA-5DDC-4EA5-9094-63BD84F420C7Q37133799-51E94C98-BDF7-4EF1-B9A8-3737DF2B73A7Q37185836-E82EB215-0E88-4836-B2B6-E80AC3BBDD84Q37265286-E0E09E43-D3BB-4CE9-AD63-CC4F6BC11EF7Q37545937-B50EF05A-53A1-4254-8F6B-51CC33086DF0Q38807857-4DDED453-F5BD-46F1-914B-628C146C14BCQ38816487-CDEA7C6C-B7A4-4B13-A855-6ED4BAEFF797Q39529503-BE0306CE-A9CF-48D0-A942-03BF1EA9AD61Q39711572-37F80F1A-5BD5-401E-AB00-BCC6EBE6CB83Q40041139-4AFD9D5F-B501-4E48-B4BE-8328AB71E11BQ40649706-E5425C79-14F4-4F2A-8ADD-6F868F803822Q41499640-1C2FBCB8-A88D-47A7-BF39-8E2A62D0FA89Q42739202-E6D40D28-F69C-4356-88AD-15AE23E23FD0Q43636050-FEDE9A76-F6D4-49D8-BC17-AFEC571751CCQ43703608-74C442BF-2785-4281-A8B4-B281E5EF6FD4Q46643138-937DC56C-6C1B-4187-81D7-032CF5242E1EQ47653552-0F0F260D-71BB-4E84-B20D-ECA0F64E5C55
P2860
Changes in glitazone use among office-based physicians in the U.S., 2003-2009.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Changes in glitazone use among office-based physicians in the U.S., 2003-2009.
@ast
Changes in glitazone use among office-based physicians in the U.S., 2003-2009.
@en
type
label
Changes in glitazone use among office-based physicians in the U.S., 2003-2009.
@ast
Changes in glitazone use among office-based physicians in the U.S., 2003-2009.
@en
prefLabel
Changes in glitazone use among office-based physicians in the U.S., 2003-2009.
@ast
Changes in glitazone use among office-based physicians in the U.S., 2003-2009.
@en
P2093
P2860
P356
P1433
P1476
Changes in glitazone use among office-based physicians in the U.S., 2003-2009
@en
P2093
Atonu Rabbani
G Caleb Alexander
Nilay Shah
P2860
P304
P356
10.2337/DC09-1834
P407
P50
P577
2010-01-26T00:00:00Z